← Back to Cases
PMCPA Case

AUTH/2864/8/16: Anonymous (non-contactable) v Boehringer Ingelheim – consultant engagement, training workshops and alleged audit-linked switching (No breach)

📅 8 March 2026 | 🖉 Dr Anzal Qurbain
📊

Key facts

⌄
Case numberAUTH/2864/8/16
PartiesAnonymous, non-contactable complainant v Boehringer Ingelheim
IssueEngagement of a consultant and his/her training and consultancy company; alleged audit/workshop funding linked to prescribing influence and coercion
Complaint received03 August 2016
Case completed19 December 2016
PublishedFebruary 2017 Code of Practice Review
Applicable Code year2014 (with consideration of 2016 Code clauses for later activities as described in the report)
Panel decisionNo breach
Clause(s) considered/listed2, 9.1, 18.1, 18.6, 19.1, 19.2, 20.1 and 21
AppealNo appeal
Notable Panel observationsComplainant provided no evidence; BI should have been aware of the HCP’s dual role; vulnerability noted re congress sponsorship documentation (unsigned agreement; no routine receipts)

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
📋

What happened

⌄
  • An anonymous, non-contactable complainant alleged a therapy-area training and consultancy company (owned by a health professional) delivered NHS-facing audits, mentoring and accredited workshops funded by multiple pharma companies including Boehringer Ingelheim.
  • The health professional was also a specialist nurse contracted by NHS organisations (including a community healthcare organisation) and was alleged to have prescribing responsibility/influence within a named CCG.
  • Allegations included: industry-funded “clinical audits” in GP surgeries leading to irregular use of a sponsor’s product; patients being initiated/switched with little consideration of alternatives; and sales increases allegedly linked to funding.
  • Further allegations: industry-funded accredited workshops (RCGP/RCN) in partnership with a CCG; “staggering” funding perceived as trying to “buy the business”; and coercive behaviour (threats that products would not be used if companies did not fund).
  • Boehringer Ingelheim described its interactions: a 2014 evening meeting where the nurse spoke (speaker fee paid by BI); two 2-day courses in April and July 2016 sponsored by BI (and another company) where BI paid for exhibition stands via contracts with the consultancy company; and a July 2016 PRIMIS (university-developed free audit tool) training day funded by BI with payment made directly to the university.
  • After notification of the complaint, BI placed ongoing/future activity involving the consultancy company on hold and issued a certified field force briefing.
  • The Panel noted BI should have been well aware of the health professional’s dual role (NHS role within the CCG and owner/director of the consultancy company) based on materials and correspondence.
⚖️

Outcome

⌄
  • No breach of the Code was ruled.
  • The Panel found the complainant provided no evidence to support the allegations and could not be contacted for further detail; the complainant bore the burden of proof on the balance of probabilities.
  • No breach was ruled in relation to alleged inducement concerns around the 2014 speaker engagement, the 2016 course sponsorship/exhibition stands, and the PRIMIS training sponsorship.
  • The Panel stated BI’s sponsorship of the health professional to attend a UK conference in 2016 was outside the scope of the complaint (no rulings made), but noted vulnerability due to lack of receipts and an unsigned agreement.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access
← All Cases Book a Free Compliance Call

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free